Role of gene mutation in the drug response enzyme in patients treated with drug clopidrogel in chhatisgarh populatio
Not Applicable
- Conditions
- Health Condition 1: I259- Chronic ischemic heart disease, unspecified
- Registration Number
- CTRI/2021/09/036214
- Lead Sponsor
- Chhattisgarh Council of Science Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients more than 18 years of age and of any gender.
Patients who have been on clopidogrel therapy for more than seven days. (75mg clopidogrel daily)
Exclusion Criteria
Patients with family history of bleeding disorders.
Pregnant and lactating women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effect of genetic polymorphisms of CYP2C19 and P2Y12 on platelet aggregation in patients on treatment with clopidogrel.Timepoint: 48 MONTHS
- Secondary Outcome Measures
Name Time Method To study the effect of genetic polymorphisms of CYP2C19 and P2Y12 on clopidogrel metabolism in patients on treatment with clopidogrel.Timepoint: 48 MONTHS